BACKGROUND: The emergence of drug resistant mycobacterium has become a signicant public
health problem creating an obstacle to effective Tuberculosis (TB) control. Freedom from TB is possible
with timely, regular, complete treatment, with assurance, prevention and management of side effects of antitubercular drugs.
Present study was conducted to evaluate common and rare adverse drug reactions (ADR) of CAT IV and CAT V to analyse
demographic, radiological and bacteriological prole and treatment outcome in MDR &XDR patients.
Aims and Objectives- To evaluate the common and rare adverse drug reactions of intensive phase treatment of Multi Drug
Resistant Tuberculosis (MDR) and Extensively Drug Resistant Tuberculosis (XDR) as per WHO-UMC Causality Assessment
Scale.
METHODS: 76 patients of MDR and XDR Tuberculosis were admitted in DR-TB (Drug Resistant TB) centre, Burdwan Medical
College and Hospital and the adverse drug reaction prole of 2nd line drugs were analysed during the intensive phase for a
year after fullling the inclusion and exclusion criteria. Treatment was given as per guidelines by Revised National TB Control
Program PMDT (Programmatic management of drug-resistant TB).
RESULTS:Adverse drug reactions on GI system were nausea 73 patients (96.10%), vomiting 70 (92.10%), acidity 41 (53.9%), and
sulphurous belching and hepatitis 1 (1.31%) each.
CONCLUSIONS: The reactions were common in rst 60 days of the regimen and in patients with BMI ≤18. Hence vigilant
monitoring is required for these types of patients during the initial period and sputum smear and culture conversion is very well
correlated with clinical and radiological improvement.